Visit Citebite Deep link provided by Citebite
Close this shade
Source:  http://jid.oxfordjournals.org/content/early/2013/06/18/infdis.jit192/T3.expansion.html

Skip Navigation

Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010

Table 3.

Human Papillomavirus (HPV) Prevalence Among Sexually Active Females Aged 14–19 Years, Overall and by Vaccination History, National Health and Nutrition Examination Surveys, 2003–2006 and 2007–2010

HPV Typea/ Vaccination History Prevalence, % (95% CI)
2003–2006 (n = 736) 2007–2010 (n = 358b) aPRc (95% CI)
Any HPV
 Overall 53.1 (48.9, 57.2) 42.9 (36.2–49.9) 0.82 (0.69–0.98)*
 Vaccinated NA 50.0 (38.3–61.6) 0.90 (0.72–1.16)
 Unvaccinated NA 38.6 (30.8–47.2) 0.77 (0.64–0.93)**
Vaccine type
 Overall 19.4 (15.7, 23.8) 9.0 (6.5–12.2) 0.47 (0.33–0.67)***
 Vaccinated NA 3.1d (1.4–6.6) 0.12 (0.05–0.29)***
 Unvaccinated NA 12.6 (9.1–17.3) 0.72 (0.50–1.02)
HR nonvaccine type
 Overall 33.5 (29.6, 37.6) 29.1 (23.0–36.0) 0.90 (0.71–1.13)
 Vaccinated NA 35.2 (24.6–47.4) 1.02 (0.72–1.43)
 Unvaccinated NA 25.3 (19.6–32.1) 0.81 (0.64–1.02)
 Alpha-9 species
  Overall 12.9 (9.7, 17.1) 12.0 (8.6–16.6) 0.97 (0.64–1.47)
  Vaccinated NA 17.8 (10.2–29.2) 1.30 (0.74–2.29)
  Unvaccinated NA 8.4 (5.2–13.5) 0.72 (0.42–1.24)
 Alpha-7 species
  Overall 12.4 (9.8, 15.6) 11.1 (9.7–14.3) 0.92 (0.62–1.38)
  Vaccinated NA 15.0 (9.0–24.0) 1.22 (0.72–2.07)
  Unvaccinated NA 8.9 (6.0–13.0) 0.74 (0.48–1.15)
  • Abbreviations: CI, confidence interval; aPR, adjusted prevalence ratio; NA, not applicable; HR, high risk.

  • a Vaccine types consist of HPV-6, -11, -16, and -18. High-risk (HR) nonvaccine types consist of HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68. Nonvaccine type alpha 9 species consist of HPV-31, -33, -35, -52, and -58. Nonvaccine type alpha 7 species consist of HPV-39, -45, -59, and -68.

  • b A total of 111 females were vaccinated (defined as a history of receipt of ≥1 vaccine dose), and 239 were unvaccinated. Data for 8 females who had no information on vaccination status are included in the overall group.

  • c Prevalence during 2007–2010 compared with prevalence during 2003–2006, adjusted for race/ethnicity and lifetime no. of sex partners.

  • d Relative standard error >30%.

  • * P < .05; **P < .01; ***P < .001, all by the F statistic, from the Wald χ2 test.

This Article

  1. J Infect Dis